A Turning Point for Kratom? Federal Officials Draw a Clearer Line Between Natural Leaf and Concentrated 7-OH

October 16, 2026 | Kratom Industry News

Federal kratom regulation entered a new phase this week as the U.S. Department of Justice announced updated scheduling actions targeting concentrated 7-hydroxymitragynine (7-OH) and related opioid compounds.

The October 9 announcement introduced revised concentration and alkaloid-ratio thresholds intended to distinguish products containing naturally occurring trace compounds from those containing elevated concentrations of 7-OH or mitragynine pseudoindoxyl (MGPI).

The developments came during a significant anniversary for the kratom community. Ten years earlier, the Drug Enforcement Administration (DEA) withdrew its controversial 2016 proposal to temporarily place kratom's primary alkaloids under Schedule I of the Controlled Substances Act.

Together, these events raise a central question for consumers, researchers, and businesses: How should federal regulators distinguish traditional botanical kratom from concentrated or chemically manipulated alkaloid products?

What Changed on October 9?

On October 9, 2026, the Department of Justice announced that the DEA would issue updated Notices of Intent incorporating new scientific recommendations from the Department of Health and Human Services (HHS).

The actions address four opioid compounds associated with the evolving market for concentrated kratom-related products:

• 7-hydroxymitragynine (7-OH)
• Mitragynine pseudoindoxyl (MGPI)
• MGM-15
• MGM-16

The most significant change involves proposed thresholds for 7-OH and MGPI.

Under the updated HHS recommendations, Schedule I controls would apply when either substance, individually or combined when both are present, meets any of the following conditions:

• Solid products: More than 1 milligram per gram.
• Liquid products: More than 1 milligram per milliliter.
• Alkaloid ratio: A mitragynine-to-7-OH, MGPI, or combined 7-OH/MGPI ratio of less than 100:1.

These are alternative criteria. A product would not need to exceed both the concentration and ratio thresholds to fall within the proposed controls.

The approach is intended to distinguish products containing relatively low levels of these compounds from those with elevated concentrations.

On October 14, the DEA published its updated Notice of Intent in the Federal Register, formally outlining the proposed scheduling approach for 7-OH and MGPI.

Importantly, these proposed thresholds do not mean that natural kratom has received federal approval or that existing restrictions have been removed.

The DEA had already temporarily placed MGPI, MGM-15, and MGM-16 into Schedule I in August 2026. Those controls remain in effect while the agency proceeds with its updated scheduling actions.

For 7-OH, the DEA had not yet issued a temporary scheduling order as of the October 9 announcement.

Why the Natural Kratom Distinction Matters

Traditional kratom leaf, derived from the Mitragyna speciosa tree, contains a complex mixture of naturally occurring alkaloids.

Mitragynine is generally the most abundant alkaloid, while 7-hydroxymitragynine typically occurs at substantially lower concentrations.

Products containing concentrated 7-OH can differ significantly from traditional kratom leaf in chemical composition, potency, and pharmacological effects.

That distinction is central to the current regulatory discussion.

The updated HHS analysis acknowledges that 7-OH occurs naturally in botanical kratom at relatively low levels. It also identifies emerging scientific information suggesting that trace amounts of MGPI may occur in certain botanical or kratom-derived products.

However, the science surrounding naturally occurring MGPI remains under investigation.

The revised threshold recommendations reflect an effort to account for these chemical differences while addressing products containing elevated concentrations of the targeted compounds.

For consumers and businesses, the distinction has practical implications.

Analytical laboratory testing, accurate alkaloid measurements, and reliable product labeling may become increasingly important as regulators evaluate whether a product falls within a particular scheduling threshold.

At the same time, chemical composition alone does not establish that a product is safe. Product quality, contamination risks, dosage, and other factors remain relevant to public health.

Ten Years After the DEA's Historic 2016 Withdrawal

October 13, 2026, marked ten years since the DEA's withdrawal of its original emergency scheduling proposal became effective.

In August 2016, the agency had announced its intention to temporarily place mitragynine and 7-hydroxymitragynine into Schedule I.

The proposal generated significant public opposition, including responses from kratom consumers, advocacy organizations, researchers, and members of Congress.

On October 13, 2016, the DEA formally withdrew its Notice of Intent and opened a public comment period to gather additional scientific and medical information.

The withdrawal did not constitute a federal determination that kratom was safe or approved. It did, however, represent a major development in the regulation of the plant and its alkaloids.

According to the American Kratom Association (AKA), advocates returned to Washington, D.C., on October 13, 2026, to commemorate that anniversary and recognize a decade of continued consumer advocacy.

The anniversary also provided an opportunity to reflect on how the regulatory debate has changed.

Ten years ago, the central concern involved the possible scheduling of kratom's primary alkaloids.

Today, much of the federal discussion focuses on distinguishing traditional botanical products from newer concentrated and chemically manipulated compounds.

Congressional Briefing Brings Consumer Experiences to Capitol Hill

The following day, October 14, the American Kratom Association reported holding a congressional briefing focused on natural kratom, concentrated opioid products, and consumer experiences.

According to the AKA, the event included personal testimony from individuals describing how kratom has affected their lives.

The organization emphasized the importance of allowing policymakers to hear directly from consumers whose access to kratom products may be affected by regulatory decisions.

Personal experiences can provide useful context about consumer behavior and perceived benefits. However, testimonials do not replace controlled scientific research evaluating effectiveness, dependence, adverse effects, or long-term safety.

The briefing illustrates the ongoing intersection of scientific research, public health concerns, consumer experiences, and federal policymaking.

What Does This Mean for Kratom Consumers?

For consumers of traditional botanical kratom, the October developments offer additional clarity about the substances federal officials are targeting.

The updated recommendations recognize that trace levels of certain compounds may differ chemically and legally from concentrated products containing substantially greater amounts.

However, several important points remain:

• Natural kratom has not received blanket federal approval. The revised scheduling approach does not override existing FDA authority or applicable laws.
• The new thresholds remain part of an ongoing regulatory process. Their final legal application depends on subsequent DEA actions.
• Some related compounds are already controlled. MGPI, MGM-15, and MGM-16 were temporarily placed in Schedule I in August 2026.
• State laws still matter. Kratom legality, product restrictions, and consumer protections vary across jurisdictions.
• Laboratory testing remains important. Reliable alkaloid testing can help establish a product's chemical composition and support regulatory compliance.

Consumers should also recognize that a product marketed as "natural" is not necessarily free from safety risks or regulatory requirements.

What Happens Next?

The DEA's updated Notices of Intent are steps in the federal temporary scheduling process.

The agency must complete the applicable procedures before implementing the proposed controls, and the exact legal implications will depend on subsequent actions.

Several questions remain for the kratom industry:

• How will the proposed thresholds be applied to finished botanical products?
• What analytical testing methods will regulators use to measure trace concentrations of 7-OH and MGPI?
• How will federal scheduling decisions interact with state-level kratom regulations?
• Will the evolving regulatory framework result in clearer standards for traditional botanical kratom?

These questions are especially relevant to manufacturers, distributors, laboratories, retailers, and consumers navigating a changing regulatory environment.

A More Precise Regulatory Conversation

A decade after the DEA's original kratom scheduling proposal, the federal discussion has become increasingly focused on specific compounds, measurable concentrations, and product composition.

The October 2026 developments illustrate that shift.

Rather than treating every product associated with kratom as chemically equivalent, the updated recommendations establish criteria intended to distinguish products with trace alkaloid concentrations from those containing elevated levels of 7-OH or MGPI.

The American Kratom Association has welcomed this distinction, characterizing it as an important development for the treatment of natural botanical kratom under federal policy.

Nevertheless, the broader questions surrounding kratom safety, appropriate regulation, product standards, and consumer access remain unresolved.

What is clear is that the chemical differences between traditional kratom leaf and concentrated alkaloid products are becoming increasingly important to federal regulatory decisions.

For consumers and the kratom industry, understanding those differences will remain essential as federal policy continues to evolve.